摘要
目的探究曲妥珠单抗联合放化疗对人表皮生长因子受体2(HER2)阳性乳腺癌患者癌胚抗原(CEA)、癌相关糖蛋白抗原(CA153)和细胞间黏附因子-1(ICAM-1)的影响。方法按照信封抽签法将110例HER2阳性乳腺癌患者分为观察组(55例,采用放化疗+曲妥珠单抗的治疗方式)与对照组(55例,采用放化疗的治疗方式),比较两组患者的临床疗效、生存时间及质量、血清肿瘤标志物水平和用药安全性。结果对照组患者经治疗后疾病缓解率(43.64%)明显低于观察组(76.36%)(P<0.05);对照组的肿瘤总生存期、无进展生存期和QOL评分等各项数据都明显低于观察组(P<0.05);两组患者治疗后CEA、CA153、ICAM-13均降低,且观察组降低幅度更显著(P<0.05);总不良反应发生率观察组(27.27%)与对照组(23.64%)比较无统计学意义(P>0.05)。结论曲妥珠单抗联合放化疗能够有效改善患者的血清CEA、CA153、ICAM-1水平,提高HER2阳性乳腺癌患者的临床疗效,且不会增加患者机体的不良反应。
Objective To investigate the effects of trastuzumab combined with chemoradiotherapy on carcinoembryonic antigen(CEA),cancer-associated glycoprotein antigen(CA153)and intercellular adhesion factor-1(ICAM-1)in human epidermal growth factor receptor 2(HER2)positive breast cancer patients and their side effects.Methods According to the envelope drawing method,110 patients who treated with HER2-positive breast cancer were divided into the observation group(55 cases)and the control group(55 cases).The patients in the control group were treated with chemotherapy and radiotherapy.On the basis of the control group,the observation group was treated with Trastuzumab.The clinical efficacy,survival time and quality,serum tumor marker levels and drug safety of the 2 groups were compared.Results The remission rate of disease in the control group(43.64%)after treatment was significantly lower than that in the observation group(76.36%)(P<0.05).The overall tumor survival,progression-free survival and QOL scores of the control group were significantly lower than those of the observation group(P<0.05).After treatment,CEA,CA153 and ICAM-13 were decreased in both groups,and the decrease was more significant in the observation group(P<0.05).There was no significant difference in the incidence of adverse reactions between the observation group(27.27%)and the control group(23.64%)(P>0.05).Conclusion Trastuzumab combined with chemoradiotherapy can effectively improve the serum CEA,CA153 and ICAM-1 levels of patients with HER2-positive breast cancer,and improve the clinical efficacy of patients with HER2-positive breast cancer,without increasing the toxic and side effects of patients.
作者
李丹丹
亢崇照
段梅艳
LI Dandan;KANG Chongzhao;DUAN Meiyan(The First Affiliated Hospital of Henan University of Science and Technology,Luoyang,471000)
出处
《实用癌症杂志》
2024年第9期1540-1543,共4页
The Practical Journal of Cancer
